DOXORUBICIN for Bladder transitional cell carcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 56 adverse event reports in the FDA FAERS database where DOXORUBICIN was used for Bladder transitional cell carcinoma.

Most Reported Side Effects for DOXORUBICIN

Side Effect	Reports	%	Deaths	Hosp.
Febrile neutropenia	8,844	10.7%	1,075	5,491
Off label use	7,858	9.5%	1,712	2,385
Disease progression	6,165	7.5%	1,384	865
Neutropenia	5,891	7.1%	927	2,104
Drug ineffective	4,598	5.6%	1,342	1,068
Pyrexia	3,697	4.5%	482	2,503
Thrombocytopenia	3,638	4.4%	645	1,330
Anaemia	3,601	4.4%	555	1,566
Product use in unapproved indication	3,502	4.2%	821	978
Nausea	2,925	3.5%	279	1,405
Sepsis	2,740	3.3%	1,481	1,198
Pneumonia	2,611	3.2%	839	1,521
Death	2,515	3.0%	2,514	299
Diarrhoea	2,330	2.8%	403	1,216
Vomiting	2,279	2.8%	310	1,233